Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$1.24
$0.00 · 0.00%
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Latest quote
$1.24
$0.00 · 0.00%
After-hours
$1.24
$0.00 · 0.00%
Sep 11, 4:10 PM ET
Regular session · ET · Market data may be delayed.
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Day range
Current $1.24
52-week range
Current $1.24
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
51
Mixed
Risk
47
Elevated Risk
Momentum
76
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Day range
Current $1.24
52-week range
Current $1.24
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 28K USD | — | 651K USD | — | 378K USD |
| Cost of goods sold | — | 6.72M USD | 5.55M USD | 1.65M USD | 3.01M USD |
| Gross profit | 28K USD | −6.72M USD | −4.9M USD | −1.65M USD | −2.63M USD |
| Research and development | 6.03M USD | 6.72M USD | 5.55M USD | 1.69M USD | 2.44M USD |
| Selling, general, and administrative | 7.48M USD | — | — | 17.01M USD | — |
| Operating expenses | 13.51M USD | 8.53M USD | 11.99M USD | 18.71M USD | 15.49M USD |
| Interest income | 436K USD | 679K USD | 6.74M USD | 1.5M USD | 3.16M USD |
| Interest expense | — | 394K USD | 134K USD | 1.12M USD | 2.29M USD |
| Depreciation and amortization | — | 96K USD | 96K USD | 1.65M USD | 1.97M USD |
| Operating income | −13.48M USD | −15.25M USD | −16.89M USD | −20.35M USD | −18.12M USD |
| Net income | −14.29M USD | −13M USD | −18.4M USD | 42.52M USD | −35.1M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.00
141.94% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 26, 2022 | 1:20 | — | — |
Effective Oct 26, 2022
1:20
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
